vs
Beam Therapeutics Inc.（BEAM）与DHT Holdings, Inc.（DHT）财务数据对比。点击上方公司名可切换其他公司
Beam Therapeutics Inc.的季度营收约是DHT Holdings, Inc.的1.1倍（$114.1M vs $107.3M），Beam Therapeutics Inc.净利率更高（214.1% vs 41.7%，领先172.4%），Beam Therapeutics Inc.同比增速更快（279.5% vs -24.5%）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
DHT控股是一家独立的国际原油运输企业，持有并运营大型原油运输船队，主要服务全球油气行业，为头部石油生产商、炼油厂和大宗商品贸易商提供跨国际核心贸易航线的原油海运服务。
BEAM vs DHT — 直观对比
营收规模更大
BEAM
是对方的1.1倍
$107.3M
营收增速更快
BEAM
高出304.0%
-24.5%
净利率更高
BEAM
高出172.4%
41.7%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $107.3M |
| 净利润 | $244.3M | $44.8M |
| 毛利率 | — | — |
| 营业利润率 | -15.3% | 44.2% |
| 净利率 | 214.1% | 41.7% |
| 营收同比 | 279.5% | -24.5% |
| 净利润同比 | 370.4% | 27.3% |
| 每股收益（稀释后） | $2.53 | $0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMDHT
| Q4 25 | $114.1M | — | ||
| Q3 25 | — | $107.3M | ||
| Q3 24 | — | $142.1M | ||
| Q4 23 | $316.2M | — | ||
| Q3 23 | — | $131.6M | ||
| Q3 22 | — | $109.9M |
净利润BEAMDHT
| Q4 25 | $244.3M | — | ||
| Q3 25 | — | $44.8M | ||
| Q3 24 | — | $35.2M | ||
| Q4 23 | $142.8M | — | ||
| Q3 23 | — | $31.0M | ||
| Q3 22 | — | $7.5M |
营业利润率BEAMDHT
| Q4 25 | -15.3% | — | ||
| Q3 25 | — | 44.2% | ||
| Q3 24 | — | 29.7% | ||
| Q4 23 | 42.0% | — | ||
| Q3 23 | — | 29.7% | ||
| Q3 22 | — | 11.1% |
净利率BEAMDHT
| Q4 25 | 214.1% | — | ||
| Q3 25 | — | 41.7% | ||
| Q3 24 | — | 24.8% | ||
| Q4 23 | 45.2% | — | ||
| Q3 23 | — | 23.5% | ||
| Q3 22 | — | 6.8% |
每股收益（稀释后）BEAMDHT
| Q4 25 | $2.53 | — | ||
| Q3 25 | — | $0.28 | ||
| Q3 24 | — | $0.22 | ||
| Q4 23 | $1.91 | — | ||
| Q3 23 | — | $0.19 | ||
| Q3 22 | — | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $81.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $1.1B |
| 总资产 | $1.5B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BEAMDHT
| Q4 25 | $1.2B | — | ||
| Q3 25 | — | $81.3M | ||
| Q3 24 | — | $73.8M | ||
| Q4 23 | $1.2B | — | ||
| Q3 23 | — | $73.9M | ||
| Q3 22 | — | $65.7M |
股东权益BEAMDHT
| Q4 25 | $1.2B | — | ||
| Q3 25 | — | $1.1B | ||
| Q3 24 | — | $1.0B | ||
| Q4 23 | $981.3M | — | ||
| Q3 23 | — | $1.0B | ||
| Q3 22 | — | $1.0B |
总资产BEAMDHT
| Q4 25 | $1.5B | — | ||
| Q3 25 | — | $1.4B | ||
| Q3 24 | — | $1.5B | ||
| Q4 23 | $1.5B | — | ||
| Q3 23 | — | $1.5B | ||
| Q3 22 | — | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | $60.9M |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | — |
| 自由现金流率自由现金流/营收 | -76.3% | — |
| 资本支出强度资本支出/营收 | 3.3% | — |
| 现金转化率经营现金流/净利润 | -0.34× | 1.36× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BEAMDHT
| Q4 25 | $-83.3M | — | ||
| Q3 25 | — | $60.9M | ||
| Q3 24 | — | $80.1M | ||
| Q4 23 | $135.1M | — | ||
| Q3 23 | — | $55.7M | ||
| Q3 22 | — | $5.5M |
自由现金流BEAMDHT
| Q4 25 | $-87.0M | — | ||
| Q3 25 | — | — | ||
| Q3 24 | — | — | ||
| Q4 23 | $131.5M | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — |
自由现金流率BEAMDHT
| Q4 25 | -76.3% | — | ||
| Q3 25 | — | — | ||
| Q3 24 | — | — | ||
| Q4 23 | 41.6% | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — |
资本支出强度BEAMDHT
| Q4 25 | 3.3% | — | ||
| Q3 25 | — | — | ||
| Q3 24 | — | — | ||
| Q4 23 | 1.1% | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — |
现金转化率BEAMDHT
| Q4 25 | -0.34× | — | ||
| Q3 25 | — | 1.36× | ||
| Q3 24 | — | 2.28× | ||
| Q4 23 | 0.95× | — | ||
| Q3 23 | — | 1.80× | ||
| Q3 22 | — | 0.73× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
DHT
暂无分部数据
